5 Key Takeaways

• 1

  Intraocular pressure (IOP) is the only modifiable risk factor in glaucoma management, making adherence to IOP-lowering medications crucial.

• 2

  Only 10% of patients persist with glaucoma drops for a year, facing challenges like side effects, drop instillation issues, and access barriers.

• 3

  The FDA approved Durysta, a biodegradable implant, in 2020, designed to release bimatoprost for 3-4 months without surgical removal.

• 4

  iDose TR, approved in 2023, is a sustained-release travoprost implant that elutes medication for up to 3 years and can be implanted during cataract surgery.

• 5

  Patients should be counseled on the temporary nature of implantable drug delivery, emphasizing ongoing glaucoma management after medication levels decline.